FY2026 Earnings Forecast for Insmed Issued By HC Wainwright

Insmed, Inc. (NASDAQ:INSM) – Research analysts at HC Wainwright raised their FY2026 earnings per share (EPS) estimates for Insmed in a research report issued on Monday, August 10th. HC Wainwright analyst A. Fein now anticipates that the biopharmaceutical company will earn ($1.86) per share for the year, up from their prior forecast of ($2.99). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Insmed’s current full-year earnings is ($1.85) per share.

Several other analysts have also recently weighed in on INSM. Guggenheim reduced their price target on Insmed from $207.00 to $205.00 and set a “buy” rating on the stock in a report on Friday, August 7th. UBS Group reiterated a “buy” rating and set a $172.00 target price on shares of Insmed in a research report on Friday, August 7th. JPMorgan Chase & Co. cut their target price on Insmed from $179.00 to $175.00 and set an “overweight” rating on the stock in a report on Monday. Wells Fargo & Company increased their price target on Insmed from $161.00 to $169.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Finally, Jefferies Financial Group restated a “buy” rating and set a $175.00 price objective on shares of Insmed in a research report on Thursday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $205.52.

Insmed Trading Down 0.2%

INSM opened at $132.28 on Thursday. The company has a market cap of $28.89 billion, a P/E ratio of -32.18 and a beta of 0.81. The company has a current ratio of 3.72, a quick ratio of 3.40 and a debt-to-equity ratio of 0.74. The company’s 50 day moving average is $106.86 and its 200-day moving average is $128.44. Insmed has a 1-year low of $90.39 and a 1-year high of $212.75.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.61. Insmed had a negative net margin of 76.94% and a negative return on equity of 123.94%. The firm had revenue of $425.49 million for the quarter, compared to the consensus estimate of $395.50 million. During the same period in the prior year, the company posted ($1.70) earnings per share. The business’s revenue for the quarter was up 296.1% on a year-over-year basis.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of INSM. Norges Bank bought a new position in Insmed during the 4th quarter valued at about $506,625,000. RTW Investments LP grew its stake in shares of Insmed by 57.0% in the fourth quarter. RTW Investments LP now owns 4,842,879 shares of the biopharmaceutical company’s stock worth $842,855,000 after acquiring an additional 1,758,321 shares during the period. Orbis Allan Gray Ltd bought a new stake in shares of Insmed in the second quarter worth approximately $153,389,000. Bank of New York Mellon Corp purchased a new position in shares of Insmed during the second quarter valued at approximately $139,966,000. Finally, State Street Corp raised its holdings in shares of Insmed by 30.6% during the fourth quarter. State Street Corp now owns 5,201,744 shares of the biopharmaceutical company’s stock valued at $905,312,000 after purchasing an additional 1,217,390 shares during the last quarter.

Insider Activity at Insmed

In other news, COO Roger Adsett sold 239,850 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $133.27, for a total transaction of $31,964,809.50. Following the transaction, the chief operating officer directly owned 98,744 shares of the company’s stock, valued at $13,159,612.88. This represents a 70.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Michael Alexander Smith sold 6,149 shares of the business’s stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $108.47, for a total value of $666,982.03. Following the sale, the insider directly owned 41,613 shares of the company’s stock, valued at $4,513,762.11. This represents a 12.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 294,440 shares of company stock valued at $37,758,548 in the last ninety days. Insiders own 2.10% of the company’s stock.

Key Insmed News

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: HC Wainwright raised its earnings outlook across 2026–2030 and maintained a Buy rating. The firm now expects smaller losses in Q3 and Q4 2026, followed by earnings of $1.62 per share in 2027, $3.38 in 2028 and $10.92 in 2030. The upgrades imply increased confidence in Insmed’s commercial growth and path to profitability.
• Positive Sentiment: Insmed partnered with a patient organization on a bronchiectasis study. The collaboration could improve patient engagement and generate additional evidence in an important respiratory-disease market. Insmed partners patient group on bronchiectasis study
• Neutral Sentiment: Recent operating results remain encouraging but profitability is still ahead. Insmed’s latest quarterly revenue rose 296.1% year over year to $425.5 million, while its $0.06-per-share loss was substantially better than expectations. However, the company remains unprofitable and analysts still expect a full-year loss.
• Neutral Sentiment: Short-interest data offered no meaningful trading signal. Reported short interest was zero with zero days to cover, but the accompanying data included an invalid “NaN” change figure, making the information unreliable.
• Negative Sentiment: COO Roger Adsett sold 239,850 shares for approximately $32.0 million. The transaction reduced his direct ownership by 70.84% and could weigh on sentiment because of its size, even though insider sales may reflect personal financial planning. Insider trading filing
• Negative Sentiment: JPMorgan lowered its INSM price target from $179 to $175 while retaining an Overweight rating. The reduction contrasts with HC Wainwright’s improved earnings outlook and may reinforce near-term caution, although the broader analyst consensus remains Buy with a $205.52 target. JPMorgan lowers expectations for Insmed stock price

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.